A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.
Also called NCT01733758
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 494 participants
- Sponsor
- Registry
-
NCT01733758
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01733758. Randomized; double masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-05-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Albiglutide 30 mg weekly
- Intervention (Drug)
- Albiglutide 50 mg weekly
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Liraglutide 0.9 mg daily
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01733758- Content hash
1fccb70c342c6d233a91e15618cf2f0a3191ecc8cb80968fd6c5f38f535def2e